Literature DB >> 22031513

Glucagon like peptide-1 receptor expression in the human thyroid gland.

Belinda Gier1, Peter C Butler, Chi K Lai, David Kirakossian, Matthew M DeNicola, Michael W Yeh.   

Abstract

BACKGROUND: Glucagon like peptide-1 (GLP-1) mimetic therapy induces medullary thyroid neoplasia in rodents. We sought to establish whether C cells in human medullary thyroid carcinoma, C cell hyperplasia, and normal human thyroid express the GLP-1 receptor.
METHODS: Thyroid tissue samples with medullary thyroid carcinoma (n = 12), C cell hyperplasia (n = 9), papillary thyroid carcinoma (n = 17), and normal human thyroid (n = 15) were evaluated by immunofluorescence for expression of calcitonin and GLP-1 receptors.
RESULTS: Coincident immunoreactivity for calcitonin and GLP-1 receptor was consistently observed in both medullary thyroid carcinoma and C cell hyperplasia. GLP-1 receptor immunoreactivity was also detected in 18% of papillary thyroid carcinoma (three of 17 cases). Within normal human thyroid tissue, GLP-1 receptor immunoreactivity was found in five of 15 of the examined cases in about 35% of the total C cells assessed.
CONCLUSIONS: In humans, neoplastic and hyperplastic lesions of thyroid C cells express the GLP-1 receptor. GLP-1 receptor expression is detected in 18% papillary thyroid carcinomas and in C cells in 33% of control thyroid lobes. The consequence of long-term pharmacologically increased GLP-1 signaling on these GLP-1 receptor-expressing cells in the thyroid gland in humans remains unknown, but appropriately powered prospective studies to exclude an increase in medullary or papillary carcinomas of the thyroid are warranted.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22031513      PMCID: PMC3412261          DOI: 10.1210/jc.2011-2407

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  31 in total

Review 1.  Incretin-based therapies: review of current clinical trial data.

Authors:  Anne Peters
Journal:  Am J Med       Date:  2010-03       Impact factor: 4.965

2.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Authors:  John B Buse; Julio Rosenstock; Giorgio Sesti; Wolfgang E Schmidt; Eduard Montanya; Jason H Brett; Marcin Zychma; Lawrence Blonde
Journal:  Lancet       Date:  2009-06-08       Impact factor: 79.321

Review 3.  GLP-1: physiological effects and potential therapeutic applications.

Authors:  Kasper Aaboe; Thure Krarup; Sten Madsbad; Jens Juul Holst
Journal:  Diabetes Obes Metab       Date:  2008-04-22       Impact factor: 6.577

4.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

Review 5.  Medullary thyroid cancer: management guidelines of the American Thyroid Association.

Authors:  Richard T Kloos; Charis Eng; Douglas B Evans; Gary L Francis; Robert F Gagel; Hossein Gharib; Jeffrey F Moley; Furio Pacini; Matthew D Ringel; Martin Schlumberger; Samuel A Wells
Journal:  Thyroid       Date:  2009-06       Impact factor: 6.568

6.  Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.

Authors:  D Russell-Jones; A Vaag; O Schmitz; B K Sethi; N Lalic; S Antic; M Zdravkovic; G M Ravn; R Simó
Journal:  Diabetologia       Date:  2009-08-14       Impact factor: 10.122

7.  Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).

Authors:  M Marre; J Shaw; M Brändle; W M W Bebakar; N A Kamaruddin; J Strand; M Zdravkovic; T D Le Thi; S Colagiuri
Journal:  Diabet Med       Date:  2009-03       Impact factor: 4.359

8.  GLP-1-based therapy for diabetes: what you do not know can hurt you.

Authors:  Peter C Butler; Sarah Dry; Robert Elashoff
Journal:  Diabetes Care       Date:  2010-02       Impact factor: 19.112

9.  Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice.

Authors:  Shuen-Ing Tschen; Sangeeta Dhawan; Tatyana Gurlo; Anil Bhushan
Journal:  Diabetes       Date:  2009-02-19       Impact factor: 9.461

10.  Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Authors:  Michael Nauck; Anders Frid; Kjeld Hermansen; Nalini S Shah; Tsvetalina Tankova; Ismail H Mitha; Milan Zdravkovic; Maria Düring; David R Matthews
Journal:  Diabetes Care       Date:  2008-10-17       Impact factor: 17.152

View more
  40 in total

1.  GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials.

Authors:  Chuqing Cao; Shuting Yang; Zhiguang Zhou
Journal:  Endocrine       Date:  2019-08-16       Impact factor: 3.633

2.  Intestinal mTOR regulates GLP-1 production in mouse L cells.

Authors:  Geyang Xu; Ziru Li; Li Ding; Hong Tang; Song Guo; Hongbin Liang; Huadong Wang; Weizhen Zhang
Journal:  Diabetologia       Date:  2015-06-03       Impact factor: 10.122

3.  Strict rules are needed for validation of G-protein-coupled receptor immunohistochemical studies in human tissues.

Authors:  Jean Claude Reubi
Journal:  Endocrine       Date:  2014-06-10       Impact factor: 3.633

Review 4.  Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors.

Authors:  Gerald H Tomkin
Journal:  World J Diabetes       Date:  2014-10-15

5.  Progesterone receptor membrane component 1 is a functional part of the glucagon-like peptide-1 (GLP-1) receptor complex in pancreatic β cells.

Authors:  Ming Zhang; Mélanie Robitaille; Aaron D Showalter; Xinyi Huang; Ying Liu; Alpana Bhattacharjee; Francis S Willard; Junfeng Han; Sean Froese; Li Wei; Herbert Y Gaisano; Stéphane Angers; Kyle W Sloop; Feihan F Dai; Michael B Wheeler
Journal:  Mol Cell Proteomics       Date:  2014-07-20       Impact factor: 5.911

6.  Impaired glucose metabolism treatment and carcinogenesis.

Authors:  Artur Matyszewski; Anna Czarnecka; Maciej Kawecki; Piotr Korzeń; Ilan J Safir; Wojciech Kukwa; Cezary Szczylik
Journal:  Oncol Lett       Date:  2015-06-04       Impact factor: 2.967

Review 7.  Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance.

Authors:  Sri Harsha Tella; Marc S Rendell
Journal:  Ther Adv Endocrinol Metab       Date:  2015-06       Impact factor: 3.565

Review 8.  Thyroid safety in patients treated with liraglutide.

Authors:  M Gallo
Journal:  J Endocrinol Invest       Date:  2013-02       Impact factor: 4.256

Review 9.  Should we still be concerned about the potential side effects of glucagon-like peptide-1 receptor agonists on thyroid C cells?

Authors:  Yang Cao; Xiao-Min Liu
Journal:  Endocrine       Date:  2014-07-18       Impact factor: 3.633

Review 10.  Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?

Authors:  Guojing Luo; Hong Liu; Hongyun Lu
Journal:  Br J Clin Pharmacol       Date:  2016-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.